Reviews/Chronic Spontaneous Urticaria Treatment/Chronic spontaneous urticaria spontaneous remission at five years
Disease Burden · CSU-DB-02 · v2
Borderline: within 4 points of the Uncertain/Doubtful boundary, so a re-grade could land either side.
This claim is about how often chronic spontaneous urticaria clears up on its own, not about any drug. The corpus holds only two studies that actually followed patients over time without treatment as the question. One followed 92 children and found that about 54% were clear by three years and about 68% by five years [11]. The other followed 220 adults for one to three years and found spontaneous clearing in about 47% of those with no identifiable cause [8]. Both point in the same direction, roughly half or more clearing over several years, but one is in children and the other does not reach five years and reports only part of its group, so neither directly measures the adult five-year figure the claim states.
Two independent prospective natural-history cohorts bear on the claim. The pediatric cohort [11] reports remission of 54% at three years and 67.7% at five years in 92 children aged 4 to 15. The adult cohort [8] followed 220 adults for one to three years and found 35% free of symptoms at one year and spontaneous remission in 47.4% of the subgroup with no identifiable cause. Both land near or above half over a multi-year window, directionally consistent with the claim, but each has a scope mismatch against adult CSU at five years. All other corpus papers are treatment trials [1-6], reviews [7, 9, 10, 12, 13, 14], a biomarker-monitoring study [15], or off-disease oncology and spondylosis papers [16-20]. The contested point: The division is whether two directionally supportive but mismatched cohorts can stand in for a purpose-built measurement. The only genuine five-year number [11] is pediatric, and the only adult number [8] stops at three years and describes a subgroup, so the magnitude is plausible while the specific adult-CSU five-year rate is not directly measured.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Spontaneous Urticaria Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only genuine five-year figure ([11], 67.7%) comes from a pediatric cohort (ages 4-15); childhood chronic urticaria has a more favourable prognosis and cannot be extrapolated to the adult CSU the claim implies.
The adult study [8] followed patients only to 3 years, so it cannot support a five-year endpoint; its 47.4% is restricted to the idiopathic no-cause subgroup, not the whole chronic-urticaria population.
Where it remains uncertain. The five-year figure is from children [11] and the adult figure is both shorter-window and subgroup-restricted [8], so neither cleanly measures adult CSU at five years.
Aleatory
Chronic urticaria resolves on different timelines across patients, so any cohort remission rate carries inherent person-to-person variation.
Epistemic
The only five-year rate is pediatric [11] and the adult cohort [8] stops at three years, so the specific adult-CSU five-year quantity is simply not measured in the corpus.
Inferential
Reading the childhood five-year rate [11] across to adult CSU requires an inference the corpus does not support, since childhood course is recognised as more favourable.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Adult cohort showing ~half spontaneous remission in the idiopathic subgroup, but over a 1-3 year window rather than five years, and as a subgroup rather than all patients.
“Spontaneous remission occurred in 47.4% of the patients in whom no cause of their urticaria and/or angioedema could be identified and in only 16.4% of the patients with physical urticaria.”
Panel auditInternal validity: medium · scope of inference: Natural course of chronic and physical urticaria/angioedema in adults over 1-3 years.Key limitations: follow-up only 1-3 years not 5 · key figure is a subgroup · mixed urticaria types
Only corpus study with an actual 5-year remission figure (67.7%), exceeding half by year 5; but population is children aged 4-15, limiting read-across to adult CSU.
“Remission rates at 1, 3, and 5 years after the onset of CU symptoms were 18.5%, 54%, and 67.7%, respectively.”
Panel auditInternal validity: medium · scope of inference: Natural history of chronic urticaria in children aged 4-15 years.Key limitations: children not adults · chronic urticaria not specifically CSU · small sample
2 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Directionally supported by two independent primary cohorts, but population and follow-up-window mismatches prevent confirming the specific adult-CSU five-year figure.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Adult CSU five-year remission cohort. The claim asserts an adult five-year rate the corpus never measures; [11] is pediatric and [8] stops at three years. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective adult CSU cohort using current CSU definitions, following untreated-course remission to at least five years and reporting the whole-population rate.
Open question: What share of adults with CSU achieve spontaneous remission by five years? Why it is still open: The only five-year figure is pediatric [11] and the only adult cohort [8] stops at three years.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19